EyeGene Inc Total Liabilities

Latest as of March 2026: ₩13.78 Billion KRW ≈ $9.34 Million USD

EyeGene Inc total liabilities. Based on the latest financial reports, EyeGene Inc (185490) has total liabilities worth ₩13.78 Billion KRW (≈ $9.34 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check EyeGene Inc (185490) asset resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of EyeGene Inc (2014–2025)

Total liabilities of EyeGene Inc from 2014 to 2025. This chart illustrates how EyeGene Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of EyeGene Inc to see how much of total assets are deployed in long-term investments.

EyeGene Inc Competitors by Total Liabilities

The table below lists competitors of EyeGene Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Diatreme Resources Ltd AU:DRX	Australia	AU$2.23 Million
180 Degree Capital Corp NASDAQ:TURN	USA	$2.85 Million
GAMEVIL Inc KQ:063080	Korea	₩266.43 Billion
StoneBridge Ventures Inc. KQ:330730	Korea	₩7.20 Billion
Lowell Resources Fund AU:LRT	Australia	AU$2.41 Million
PA Nova S.A. WAR:NVA	Poland	zł481.44 Million
Lida Holdings Ltd TW:4552	Taiwan	NT$1.64 Billion
Linz Textil Holding AG VI:LTH	Austria	€12.40 Million

Liability Composition Analysis (2014–2025)

This chart breaks down EyeGene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of EyeGene Inc.

Liquidity & Leverage Metrics

EyeGene Inc Total Liabilities Ratios Explained

EyeGene Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	4.37	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.21	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how EyeGene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for EyeGene Inc (2014–2025)

The table below shows the annual total liabilities of EyeGene Inc from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩13.80 Billion ≈ $9.35 Million	-7.91%
2024-12-31	₩14.98 Billion ≈ $10.15 Million	+8.83%
2023-12-31	₩13.77 Billion ≈ $9.33 Million	+0.85%
2022-12-31	₩13.65 Billion ≈ $9.25 Million	-14.79%
2021-12-31	₩16.02 Billion ≈ $10.86 Million	-49.18%
2020-12-31	₩31.53 Billion ≈ $21.37 Million	+11.49%
2019-12-31	₩28.28 Billion ≈ $19.16 Million	-7.88%
2018-12-31	₩30.70 Billion ≈ $20.80 Million	+370.07%
2017-12-31	₩6.53 Billion ≈ $4.43 Million	+175.39%
2016-12-31	₩2.37 Billion ≈ $1.61 Million	+51.49%
2015-12-31	₩1.57 Billion ≈ $1.06 Million	-7.33%
2014-12-31	₩1.69 Billion ≈ $1.14 Million	--

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$49.56 Million

₩73.13 Billion KRW

Market Cap Rank

#21748 Global

#1313 in Korea

Share Price

₩1692.00

Change (1 day)

-1.23%

52-Week Range

₩1193.00 - ₩2375.00

All Time High

₩50300.00